Literature DB >> 9854582

Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature.

S L Smith1, S A Branton, A J Avino, J K Martin, P J Klingler, G B Thompson, C S Grant, J A van Heerden.   

Abstract

BACKGROUND: Vasoactive intestinal polypeptide (VIP)-secreting tumors of the pancreas represent a rare subtype of pancreatic islet cell tumors with an estimated incidence of 0.2 to 0.5 per million per year. We provide data on a relatively large series of patients with VIP-secreting tumors and review current literature regarding this specific entity.
METHODS: A retrospective review was performed of all patients with VIP-secreting tumors of the pancreas treated from 1977 to 1992 at our institution. Presenting signs, symptoms, mode of diagnosis, extent of disease, surgical resectability, tumor size, treatments, hormone levels, and survival were assessed.
RESULTS: Eighteen patients were identified, 9 male and 9 female. Ages ranged from 23 to 74 years (mean 51 years). Secretory diarrhea was the most common symptom, occurring in 16 of 18 patients (89%). The most common tumor location was the tail of the pancreas (9 patients). Fourteen patients (78%) had liver metastasis at diagnosis. Curative resections were attempted in only 5 patients (28%). The mean survival was 3.6 years with the longest disease-free survival being 15 years and longest overall survival 15 years.
CONCLUSIONS: VIP-secreting tumors are extremely rare entities and usually metastatic at the time of diagnosis. Despite advanced disease, these patients can have extended survival.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9854582     DOI: 10.1067/msy.1998.92005

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  18 in total

1.  Vasoactive intestinal polypeptide-secreting tumor (VIPoma) with liver metastases: dramatic and durable symptomatic benefit from hepatic artery embolization, a case report.

Authors:  C C Case; K Wirfel; R Vassilopoulou-Sellin
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 2.  Less common neoplasms of the pancreas.

Authors:  Abby-L Mulkeen; Peter-S Yoo; Charles Cha
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

Review 3.  Gastrointestinal manifestations of endocrine disease.

Authors:  Christina Maser; Arnbjorn Toset; Sanziana Roman
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

4.  Enucleation of pancreatic lesions: indications, outcomes, and risk factors for clinical pancreatic fistula.

Authors:  Taiping Zhang; Jianwei Xu; Tianxiao Wang; Quan Liao; Menghua Dai; Yupei Zhao
Journal:  J Gastrointest Surg       Date:  2013-10-08       Impact factor: 3.452

Review 5.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Authors:  Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

6.  A calcitonin and vasoactive intestinal peptide-producing pancreatic endocrine tumor associated with the WDHA syndrome.

Authors:  Tatsunosuke Ichimura; Satoshi Kondo; Shunichi Okushiba; Toshiaki Morikawa; Hiroyuki Katoh
Journal:  Int J Gastrointest Cancer       Date:  2003

Review 7.  Pancreatic VIPomas: subject review and one institutional experience.

Authors:  Amir A Ghaferi; Karen A Chojnacki; William D Long; John L Cameron; Charles J Yeo
Journal:  J Gastrointest Surg       Date:  2008-02       Impact factor: 3.452

8.  Laparoscopic vs open resection of pancreatic endocrine neoplasms: single institution's experience over 14 years.

Authors:  Andrew A Gumbs; Philippe Grès; Fabio Madureira; Brice Gayet
Journal:  Langenbecks Arch Surg       Date:  2008-01-10       Impact factor: 3.445

9.  Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?

Authors:  Laureano Fernández-Cruz; Laia Blanco; Rebeca Cosa; Héctor Rendón
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

10.  Biology and treatment of metastatic gastrointestinal neuroendocrine tumors.

Authors:  Jonathan R Strosberg; Aejaz Nasir; Pamela Hodul; Larry Kvols
Journal:  Gastrointest Cancer Res       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.